Intrommune to Present at Biotech Showcase™ 2020
New York, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics will attend and present at the upcoming Biotech Showcase™, which occurs during the annual J.P. Morgan Biotechnology Healthcare Conference.
Date/Time: Monday, January 13, 2020; 10:30 am PSTLocation: Hilton San Francisco Union SquareTrack: Franciscan B (Ballroom level)Who: Michael Nelson, CEO, IntrommuneWhat: Overview of Intrommune’s Oral Mucosal Immunotherapy (OMIT) treatment for food allergies. Intrommune’s lead product, INT301, is being developed for the treatment of peanut allergy. INT301’s unique formulation is designed to desensitize an individual with peanut allergy and is delivered via a fully-functional toothpaste.
INTERVIEWS AVAILABLEInterviews with key Intrommune executives are available: Michael Nelson, JD, Chief Executive Officer Erick Berglund, PhD, Chief Scientific Officer William Reisacher, MD, Senior Scientific Advisor
To arrange interviews please contact: John F. Kouten, JFK Communications, Inc. firstname.lastname@example.org 609-241-7352
About Peanut and Other Food AllergiesFood allergies affect an estimated 220 million people, including more than 9 million adults and 6 million children in the U.S. Management of food allergies currently focuses on avoidance of exposure to triggering foods, though many such foods such as peanuts are common ingredients in food products and therefore difficult to avoid. Many people with peanut allergy are accidentally exposed and experience potentially life-threatening reactions, including anaphylaxis, each year. Unfortunately, there are no FDA-approved therapies for any food allergy, an area of tremendous unmet medical need.
About Oral Mucosal ImmunotherapyOral mucosal immunotherapy (OMIT) uses a specially formulated toothpaste to stabilize and deliver allergenic proteins to immunologically active areas of the oral cavity with the greatest potential for allergy desensitization. Success with allergy immunotherapy hinges on consistent exposure of a patient’s immune system to gradually “desensitize” the patient to the specific allergy trigger over time. OMIT promises advantages over other approaches to allergy immunotherapy due to its targeted delivery, simplified administration, and support of reliable, long-term adherence.
About Intrommune TherapeuticsIntrommune, dedicated to improving and protecting the lives of people with food allergy, is developing the revolutionary oral mucosal immunotherapy (OMIT) treatment platform for food allergies. OMIT is a long-term, patient-friendly, disease-modifying solution for the 220 million people, including more than 9 million adults and 6 million children in the U.S., who suffer from life-altering food allergies. Intrommune’s lead product, INT301, is expected to be a safe, effective and convenient therapy for patients who suffer from peanut allergy.
The Keiretsu Forum, a global investment community of accredited angel investors, has engaged in a thorough diligence process with Intrommune and has issued a positive report. To access this report, please visit: http://www.intrommune.com/keiretsu-dd
For more information on Intrommune Therapeutics, please visit http://www.intrommune.com
Cautionary Statement Regarding Forward Looking StatementsThis release may contain “forward-looking statements.” Forward-looking statements are identified by certain words or phrases such as “may,” “will,” “aim,” “will likely result,” “believe,” “expect,” “will continue,” “anticipate,” “estimate,” “intend,” “plan,” “contemplate,” “seek to,” “future,” “objective,” “goal,” “project,” “should,” “will pursue” and similar expressions or variations of such expressions. These forward looking statements reflect the company’s current expectations about its future plans and performance. These forward-looking statements rely on a number of assumptions and estimates which could be inaccurate and which are subject to risks and uncertainties. Actual results could vary materially from those anticipated or expressed in any forward-looking statement made by the company. The company disclaims any obligation or intent to update the forward-looking statements in order to reflect events or circumstances after the date of this release. This release does not contain or constitute an offer to sell or a solicitation of any offer to buy securities in the United States or in any other jurisdiction.
John F. Kouten JFK Communications, Inc. 609-241-7352 email@example.com